北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 期刊论文
学科主题: 临床医学
题名:
Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer
作者: Li, You-quan; Shi, An-hui; Li, Fu-hai; Yu, Rong; Zhu, Guang-ying
关键词: Non-small-cell lung cancer ; Concurrent chemoradiotherapy ; Cisplatin docetaxel ; Toxicity
刊名: CHINESE JOURNAL OF CANCER RESEARCH
发表日期: 2011-06-01
DOI: 10.1007/s11670-011-0129-9
卷: 23, 期:2, 页:129-133
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: THORACIC RADIOTHERAPY ; FOLLOW-UP ; CHEMOTHERAPY ; TRIAL ; CARBOPLATIN ; PACLITAXEL ; SURVIVAL
英文摘要:

To evaluate the maximum tolerated dose (MTD) of docetaxel (DCT) and cisplatin (DDP) concurrently with three dimensional (3D) conformal radiotherapy or IMRT for patients with locally advanced non-small cell lung cancer (stage IIIa and IIIb) after 2-4 cycles of induction chemotherapy.

Fourteen patients with histological/cytological proven stage III non-small-cell lung cancer were eligible. 3D or IMRT radiotherapy (60-70Gy in 30-35 fractions, 6-7weeks, 2 Gy/fraction) was delivered concurrently with cisplatin and docetaxel, 2 cycles during concurrent chemoradiotherapy (CCRT). The level I dosage was composed of 56 mg/m(2) DCT, on day 1 and 28mg/m(2) DDP, on day 1 and day 2. The level II was composed of 60 mg/m(2) DCT, on day 1 and 30 mg/m(2) DDP, on day 1 and day 2. The level III was composed of 64 mg/m(2) DCT, on day 1 and 32 mg/m(2) DDP, on day 1 and day 2.

Fourteen patients were allocated and finished concurrent chemoradiotherapy. The dose-limiting neutropenia was at the dose Level III (64 mg/m(2)) and occurred in 2 of 5 patients. No dose limiting non-hematologic or hematologic toxicity occurred in the other patients.

Patients with locally advanced non-small cell lung cancer may tolerate 60mg/m(2) docetaxel and 60mg/m(2) cisplatin for 2 cycles during concurrent radiotherapy after 2-3 cycles of induction chemotherapy.

语种: 英语
所属项目编号: 30870738
项目资助者: National Natural Science Foundation of China
WOS记录号: WOS:000290804600008
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/52266
Appears in Collections:北京大学临床肿瘤学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Dept Radiat Oncol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China

Recommended Citation:
Li, You-quan,Shi, An-hui,Li, Fu-hai,et al. Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer[J]. CHINESE JOURNAL OF CANCER RESEARCH,2011,23(2):129-133.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Li, You-quan]'s Articles
[Shi, An-hui]'s Articles
[Li, Fu-hai]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Li, You-quan]‘s Articles
[Shi, An-hui]‘s Articles
[Li, Fu-hai]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace